IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
Provided By GlobeNewswire
Last update: Mar 13, 2025
NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2024.
Read more at globenewswire.comNASDAQ:INAB (5/29/2025, 11:39:53 AM)
0.1491
+0.01 (+5%)
Find more stocks in the Stock Screener
INAB Latest News and Analysis
3 days ago - ChartmillThese stocks are moving in today's after hours sessionLet's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.
